| Comparative adverse effect profiles of platinum drugs MJ McKeage Drug safety 13 (4), 228-244, 1995 | 421 | 1995 |
| Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug LR Kelland, G Abel, MJ McKeage, M Jones, PM Goddard, M Valenti, ... Cancer research 53 (11), 2581-2586, 1993 | 388 | 1993 |
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non–small-cell lung cancer PN Lara Jr, JY Douillard, K Nakagawa, J Von Pawel, MJ McKeage, ... Journal of Clinical Oncology 29 (22), 2965-2971, 2011 | 359 | 2011 |
| Mechanisms of cytotoxicity and antitumor activity of gold (I) phosphine complexes: the possible role of mitochondria MJ McKeage, L Maharaj, SJ Berners-Price Coordination Chemistry Reviews 232 (1-2), 127-135, 2002 | 336 | 2002 |
| Lobaplatin: a new antitumour platinum drug MJ McKeage Expert opinion on investigational drugs 10 (1), 119-128, 2001 | 324 | 2001 |
| Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes MJ McKeage, SJ Berners-Price, P Galettis, RJ Bowen, W Brouwer, L Ding, ... Cancer chemotherapy and pharmacology 46, 343-350, 2000 | 264 | 2000 |
| Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs D Screnci, MJ McKeage, P Galettis, TW Hambley, BD Palmer, BC Baguley British journal of cancer 82 (4), 966-972, 2000 | 249 | 2000 |
| In vitro antitumour and hepatotoxicity profiles of Au (I) and Ag (I) bidentate pyridyl phosphine complexes and relationships to cellular uptake JJ Liu, P Galettis, A Farr, L Maharaj, H Samarasinha, AC McGechan, ... Journal of Inorganic Biochemistry 102 (2), 303-310, 2008 | 237 | 2008 |
| Nucleolar damage correlates with neurotoxicity induced by different platinum drugs MJ McKeage, T Hsu, D Screnci, G Haddad, BC Baguley British Journal of Cancer 85 (8), 1219-1225, 2001 | 196 | 2001 |
| ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK … BC Cho, DW Kim, A Bearz, SA Laurie, M McKeage, G Borra, K Park, ... Journal of Thoracic Oncology 12 (9), 1357-1367, 2017 | 193 | 2017 |
| Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches D Screnci, MJ McKeage Journal of inorganic biochemistry 77 (1-2), 105-110, 1999 | 187 | 1999 |
| Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer MJ McKeage, BC Baguley Cancer 116 (8), 1859-1871, 2010 | 171 | 2010 |
| Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons NN Jong, T Nakanishi, JJ Liu, I Tamai, MJ McKeage Journal of Pharmacology and Experimental Therapeutics 338 (2), 537-547, 2011 | 157 | 2011 |
| Structural and solution chemistry of gold (I) and silver (I) complexes of bidentate pyridyl phosphines: selective antitumour agents SJ Berners-Price, RJ Bowen, P Galettis, PC Healy, MJ McKeage Coordination Chemistry Reviews 185, 823-836, 1999 | 155 | 1999 |
| Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer MJ McKeage, J Von Pawel, M Reck, MB Jameson, MA Rosenthal, ... British Journal of Cancer 99 (12), 2006-2012, 2008 | 144 | 2008 |
| Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss SMF Jamieson, J Liu, B Connor, MJ McKeage Cancer chemotherapy and pharmacology 56, 391-399, 2005 | 140 | 2005 |
| Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed Y Yosaatmadja, S Silva, JM Dickson, AV Patterson, JB Smaill, ... Journal of structural biology 192 (3), 539-544, 2015 | 135 | 2015 |
| Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. MJ McKeage, F Raynaud, J Ward, C Berry, D O'dell, LR Kelland, B Murrer, ... Journal of clinical oncology 15 (7), 2691-2700, 1997 | 129 | 1997 |
| Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Zalcberg, M Millward, J Bishop, M McKeage, A Zimet, G Toner, ... Journal of clinical oncology 16 (5), 1948-1953, 1998 | 127 | 1998 |
| A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration MJ McKeage, P Mistry, J Ward, FE Boxall, S Loh, C O'Neill, P Ellis, ... Cancer chemotherapy and pharmacology 36, 451-458, 1995 | 121 | 1995 |
Bruce BaguleyEmeritus Distinguished Professor, the University of Auckland在 auckland.ac.nz 的电子邮件经过验证
